Research Directions After the DAPA-STEMI Trial

Authors
Category Primary study
JournalAmerican journal of therapeutics
Year 2026
A significant step toward the role of sodium-glucose cotransporter-2 (SGLT2) inhibitors beyond chronic heart failure and diabetes to the acute management of ST-segment elevation myocardial infarction (STEMI) is the recently published DAPA-STEMI randomized clinical trial in “American Journal of Therapeutics 2026; 33:e292–e301.” Despite the lack of crucial differences in infarct size, ST-segment resolution, inflammatory markers, or short-term clinical outcomes, the study results show significant improvement in left ventricular ejection fraction (LVEF) among patient who had baseline LVEF of ≤40%. © 2026 Wolters Kluwer Health, LLC. All rights reserved.
Epistemonikos ID: 936eaf4c3002c79cb16ae15dc71bd20ece2fc539
First added on: Aug 20, 2026